STOCK TITAN

Journey Medical Corporation (DERM) Stock News

DERM NASDAQ

Journey Medical Corporation develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. The company is a commercial-stage dermatology pharmaceutical issuer with a portfolio of branded prescription drugs marketed in the United States.

Recurring news for DERM centers on quarterly and annual financial results, corporate updates, and commercialization progress across its dermatology portfolio. Company updates frequently discuss Emrosi™, a modified-release minocycline product approved for inflammatory lesions of rosacea in adults, including payer access, group purchasing organization contracts, prescription demand, product revenue, and clinical data presentations or publications for Emrosi/DFD-29.

Rhea-AI Summary

Journey Medical (Nasdaq: DERM) reported third-quarter 2026 revenue of $19.0 million, up 8% from the prior-year quarter. Emrosi revenue rose 84% to $9.0 million, with approximately 40,000 total prescriptions. Gross margin increased to 69% from 67%. GAAP net loss narrowed to $1.315 million, or $0.05 per share, from $2.315 million, or $0.09 per share.

Selling, general and administrative expenses rose to $12.593 million from $12.054 million, including a $1.744 million vendor settlement expense. Non-GAAP adjusted EBITDA increased to $3.516 million from $1.389 million. For the first nine months, revenue reached $53.438 million versus $45.779 million, while net loss narrowed to $3.857 million from $10.184 million. Cash fell to $22.323 million at September 30, 2026, from $24.090 million at year-end 2025. Journey expects its expanded sales force and additional health-plan formulary coverage to support further Emrosi adoption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
Rhea-AI Summary

Journey Medical (DERM) will release its third quarter 2026 financial results after U.S. financial markets close on November 12, 2026. Management will host a conference call and audio webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update. A webcast replay will remain available for approximately 30 days after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
earnings date
-
Rhea-AI Summary

Journey Medical Corporation (DERM)/b) will participate in two investor conferences in September 2026.Co-Founder, President and CEO Claude Maraoui is scheduled for the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on Thursday, September 10, 2026, in New York City in a 1x1 meetings format. He is also scheduled for the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 10:00 a.m. ET, also in New York City, featuring a presentation and 1x1 meetings.

A webcast of the H.C. Wainwright presentation will be available on the News and Events page of the Investors section of Journey Medical’s website for approximately 30 days after the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
none
Rhea-AI Summary

Longeveron (NASDAQ: LGVN) appointed Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, joining the executive leadership team and succeeding Marie Washburn, who returns to her prior role as Corporate Controller.

According to Longeveron, Jhaveri brings over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector and prior CFO roles at Opus Genetics (Nasdaq: IRD), Insilico Medicine (HKEX: 3696.HK) and Journey Medical (Nasdaq: DERM). The company also highlighted ongoing development of its stem cell therapy laromestrocel, with top-line data from a Phase 2b trial in HLHS expected in September 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.99%
Tags
none
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) reported second quarter 2026 total revenue of $18.5 million, up 23% from $15.0 million a year earlier, driven by Emrosi® revenue of $8.1 million. Gross margin was 67%, unchanged year over year, and selling, general and administrative expenses declined to $10.9 million, down $1.0 million.

GAAP net loss narrowed to $0.3 million, or $(0.01) per share, versus a $3.8 million loss, or $(0.16) per share, in 2025. Non-GAAP Adjusted EBITDA turned positive at $2.9 million for the quarter. Cash and cash equivalents were $25.6 million at June 30, 2026, compared with $24.1 million at year-end 2025. Emrosi® total prescriptions reached about 36,000 in Q2 2026, versus 30,000 in Q1 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. Management will host a conference call and live audio webcast the same day at 4:30 p.m. ET to discuss results and provide a corporate update.

U.S. participants can dial 1-866-777-2509, international participants 1-412-317-5413, or register online to receive dial-in details. The webcast will be available via the Investors section of Journey Medical’s website and remain accessible for approximately 30 days after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
earnings date
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) announced that Co-Founder, President and CEO Claude Maraoui will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026. The virtual session is scheduled for 5:00 p.m. ET, with registration via the A.G.P. conference link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) reported first quarter 2026 revenue of $16.0 million, up 21% year-over-year. Emrosi® revenue rose to $6.3 million. Gross margin was 61.0%, including a $1.3 million non-recurring non-cash inventory write-down.

Net loss narrowed to $2.2 million, while Adjusted EBITDA turned positive at $0.6 million. Cash and equivalents increased to $27.2 million. Emrosi® prescriptions reached 29,968, and a new GPO contract expands access to about 85% of U.S. commercial lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.35%
Tags
-
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) will release first quarter 2026 financial results after U.S. markets close on Wednesday, May 13, 2026.

Management will host a conference call and audio webcast on May 13, 2026 at 4:30 p.m. ET. Domestic dial-in is 1-866-777-2509; international dial-in is 1-412-317-5413. Registration is available at the provided URL and a replay will be available for ~30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
earnings date
Rhea-AI Summary

Journey Medical (Nasdaq: DERM) expanded payer access for Emrosi™, increasing commercial lives reached from approximately 100 million to over 150 million as of April 1, 2026.

Approximately 85% of U.S. commercial lives now have access after contracting with a third major GPO. The company expects expanded access to support prescription growth and improved brand profitability as formulary adoption progresses through 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.20%
Tags
none

FAQ

What is the current stock price of Journey Medical (DERM)?

Journey Medical (DERM) last closed at $3.90.

What is the market cap of Journey Medical (DERM)?

The market cap of Journey Medical (DERM) is approximately $110.1M.